Risk of therapy-related secondary leukemia in hodgkin lymphoma: The stanford university experience over three generations of clinical trials

Journal of Clinical Oncology

Volumn 31, Issue 5, 2013, Pages 592-598

  Koontz, Michael Zach ^a   Horning, Sandra J ^a   Balise, Raymond ^a   Greenberg, Peter L ^a   Rosenberg, Saul A ^a   Hoppe, Richard T ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SPLENECTOMY;

ACADEMIC MEDICAL CENTERS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DATABASES, FACTUAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MECHLORETHAMINE; MELPHALAN; METHOTREXATE; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK; VINBLASTINE; VINCRISTINE;

EID: 84875410400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.5791     Document Type: Article

References (49)

1. Boivin JF, Hutchison GB, Zauber AG, et al: Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87: 732-741, 1995
2. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12: 312-325, 1994 (Pubitemid 24056405)
3. Hoppe RT: Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8:115- 118, 1997 (suppl 1)
4. Devereux S, Selassie TG, Vaughan Hudson G, et al: Leukaemia complicating treatment for Hodgkin's disease: The experience of the British National Lymphoma Investigation. BMJ 301: 1077-1080, 1990 (Pubitemid 20381133)
5. Kaldor JM, Day NE, Clarke EA, et al: Leukemia following Hodgkin's disease. N Engl J Med 322: 7-13, 1990 (Pubitemid 20023826)
6. Zinzani PL, Fiacchini M, Mazza P, et al: Fifteen-year experience in Hodgkin's disease: Role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia. Haematologica 76: 305-310, 1991
7. Thirman MJ, Larson RA: Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 10: 293-320, 1996 (Pubitemid 26097342)
8. Brusamolino E, Anselmo AP, Klersy C, et al: The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: A case-control study. Haematologica 83: 812-823, 1998 (Pubitemid 28496170)
9. Josting A, Wiedenmann S, Franklin J, et al: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21: 3440-3446, 2003 (Pubitemid 46594076)
10. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4: 830-837, 1986 (Pubitemid 16080935)
11. Rodriguez MA, Fuller LM, Zimmerman SO, et al: Hodgkin's disease: Study of treatment intensities and incidences of second malignancies. Ann Oncol 4: 125-131, 1993 (Pubitemid 23061313)
12. van Leeuwen FE, Chorus AM, van den Belt- Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12: 1063-1073, 1994 (Pubitemid 24145338)
13. Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leukemias. Haematologica 84: 937-945, 1999 (Pubitemid 29516926)
14. Andersen MK, Christiansen DH, Jensen BA, et al: Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br J Haematol 114: 539-543, 2001 (Pubitemid 32953630)
15. Swerdlow AJ, Higgins CD, Smith P, et al: Second cancer risk after chemotherapy for Hodgkin's lymphoma: A collaborative British cohort study. J Clin Oncol 29: 4096-4104, 2011
16. Pedersen-Bjergaard J, Andersen MK: Secondary or therapy-related MDS and AML and their chromosome aberrations: Important to study but difficult to establish causality. Haematologica 83: 481-482, 1998 (Pubitemid 28331163)
17. Henry-Amar M, Dietrich PY: Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 7: 369-387, 1993 (Pubitemid 23115859)
18. Mauch PM, Canellos GP, Rosenthal DS, et al: Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol 3: 501-505, 1985 (Pubitemid 15111398)
19. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Longterm results. J Clin Oncol 22: 2835-2841, 2004 (Pubitemid 41079901)
20. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484, 1992
21. Horning SJ, Hoppe RT, Mason J, et al: Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15: 1736-1744, 1997 (Pubitemid 27209499)
22. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363: 640-652, 2010
23. Hoppe RT, Horning SJ, Hancock SL, et al: Current Stanford clinical trials for Hodgkin's disease. Recent Results Cancer Res 117: 182-190, 1989
24. Horning SJ: The Stanford Hodgkin's disease (HD) studies: An update. Leukemia 5: 53-55, 1991 (suppl 1)
25. Carbone PP, Kaplan HS, Musshoff K: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31: 1860-1861, 1971
26. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11: 2258-2272, 1993 (Pubitemid 23332265)
27. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199, 1982 (Pubitemid 12073508)
28. Rosenberg SA, Kaplan HS: The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11: 5-22, 1985 (Pubitemid 15169347)
29. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20: 630-637, 2002 (Pubitemid 34111368)
30. Horning SJ, Hoppe RT, Hancock SL, et al: Vinblastine, bleomycin, and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6: 1822-1831, 1988 (Pubitemid 19089064)
31. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007 (Pubitemid 350002966)
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
33. Kramer CY: Extension of multiple range tests to group means with unequal number of replications. Biometrics 12: 307-310, 1956
34. Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187-220, 1972
35. Freeman GH, Halton JH: Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 38: 141-149, 1951
36. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47: 583-621, 1952
37. Christiansen DH, Andersen MK, Pedersen- Bjergaard J: Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104: 1474-1481, 2004 (Pubitemid 39166527)
38. Pedersen-Bjergaard J, Andersen MK, Andersen MT, et al: Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22: 240-248, 2008 (Pubitemid 351250527)
39. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19: 47-84, 1992
40. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395, 2003 (Pubitemid 36682817)
41. Engert A, Diehl V, Franklin J, et al: Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27: 4548-4554, 2009
42. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318: 76-81, 1988 (Pubitemid 18029298)
43. Horning SJ, Williams J, Bartlett NL, et al: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18: 972-980, 2000 (Pubitemid 30123772)
44. Aversa SM, Trentin C, SorarùM, et al: Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. Leuk Lymphoma 50: 1214-1216, 2009
45. Mistry AR, Felix CA, Whitmarsh RJ, et al: DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 352: 1529-1538, 2005 (Pubitemid 40517093)
46. Loeffler M, Brosteanu O, Hasenclever D, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease: International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16: 818-829, 1998 (Pubitemid 28108713)
47. Franklin J, Pluetschow A, Paus M, et al: Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials. Ann Oncol 17: 1749-1760, 2006 (Pubitemid 44884048)
48. Franklin JG, Paus MD, Pluetschow A, et al: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 4:CD003187, 2005
49. Southwest Oncology Group: Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma. http://clinicaltrials.gov/show/NCT00822120